About
Samir Ounzain is a molecular biologist and entrepreneur who co-founded HAYA Therapeutics and serves as its CEO. His work focuses on long non-coding RNAs and the regulatory genome, with prior research at Lausanne University Hospital (CHUV) contributing to discoveries including Wisper, CARMEN, and Meteor. HAYA has raised venture financing from investors including Apollo Health Ventures, but no public evidence shows Ounzain primarily operating a fund or deploying personal investment capital.
Areas of interest
longevityhealthy agingbiotechRNA therapeuticsregulatory genomelong non-coding RNAscardiovascular diseaseheart failurefibrosisobesitymetabolic diseaseprecision medicine